药学学报, 2019, 54(11): 1881-1887
张钰浩, 颜才川, 王芳, 李宝馨, 杨宝峰. 中药影响hERG钾通道致长-QT综合征机制的研究进展[J]. 药学学报, 2019, 54(11): 1881-1887.
ZHANG Yu-hao, YAN Cai-chuan, WANG Fang, LI Bao-xin, YANG Bao-feng. Advances in research on the mechanism of long-QT syndrome caused by traditional Chinese medicine affecting hERG potassium channel[J]. Acta Pharmaceutica Sinica, 2019, 54(11): 1881-1887.

张钰浩, 颜才川, 王芳, 李宝馨, 杨宝峰
哈尔滨医科大学药学院, 黑龙江 哈尔滨 150081
关键词:    中药      心脏毒性      长-QT综合征      hERG     
Advances in research on the mechanism of long-QT syndrome caused by traditional Chinese medicine affecting hERG potassium channel
ZHANG Yu-hao, YAN Cai-chuan, WANG Fang, LI Bao-xin, YANG Bao-feng
School of Pharmacy, Harbin Medical University, Harbin 150081, China
Drug-induced cardiotoxicity is recently a major concern. Cardiotoxicity is the leading cause of drug withdrawal from the market. Long-QT syndrome is one of the most important manifestations of cardiotoxicity. hERG potassium channel is an important target of drug-induced arrhythmia and antiarrhythmia drugs. Traditional Chinese medicine is a traditional medicine in China with a long history and a wide range of clinical use. However, the multi-organ toxicity caused by traditional Chinese medicine is still a problem to be solved. Some traditional Chinese medicines already in clinical use have been withdrawn from the market because of their potential cardiotoxicity or severe arrhythmias. The cardiac toxicity of more than 50 kinds of traditional Chinese medicines causing arrhythmia was reported, while more than 20 of them are induced by affecting on the hERG potassium channels. Therefore, finding out the mechanism of drug-induced long-QT syndrome and the regulatory target of drug intervention is the key research goal in today's medical field. In this paper, we summarized the mechanisms of long-QT syndrome induced by traditional Chinese medicine with Ikr/hERG potassium channel as the main target. It provides a theoretical basis for the rational use of related traditional Chinese medicine in clinical practice, the avoidance of cardiac toxicity and the development of regulatory targets for drug intervention.
Key words:    traditional Chinese medicine    cardiotoxicity    long QT syndrome    hERG   
收稿日期: 2019-05-14
DOI: 10.16438/j.0513-4870.2019-0369
基金项目: 国家自然科学基金资助项目(81673636).
PDF(400KB) Free
张钰浩  在本刊中的所有文章
颜才川  在本刊中的所有文章
王芳  在本刊中的所有文章
李宝馨  在本刊中的所有文章
杨宝峰  在本刊中的所有文章

[1] Abriel H, Zaklyazminskaya EV. Cardiac channelopathies: genetic and molecular mechanisms[J]. Gene, 2013, 517: 1-11.
[2] Garcia-Elias A, Benito B. Ion channel disorders and sudden cardiac death[J]. Int J Mol Sci, 2018, 19: 692.
[3] Vaidyanathan R, Reilly L, Eckhardt LL, et al. Caveolin-3 microdomain: arrhythmia implications for potassium inward rectifier and cardiac sodium channel[J]. Front Physiol, 2018, 9: 1548.
[4] Giudicessi JR, Wilde AAM, Ackerman MJ, et al. The genetic architecture of long QT syndrome: a critical reappraisal[J]. Trends Cardiovasc Med, 2018, 28: 453-464.
[5] Choy AM, Lang CC, Chomsky DM, et al. Normalization of acquired QT prolongation in humans by intravenous potassium[J]. Circulation, 1997, 96: 2149-2154.
[6] Roden DM, Viswanathan PC. Genetics of acquired long QT syndrome[J]. J Clin Invest, 2005, 115: 2025-2032.
[7] Kenigsberg DN, Khanal S, Kowalski M, et al. Prolongation of the QTc interval is seen uniformly during early transmural ischemia[J]. J Am Coll Cardiol, 2007, 49: 1299-1305.
[8] Shimoda LA, Polak J. Hypoxia. 4. Hypoxia and ion channel function[J]. Am J Physiol Cell Physiol, 2011, 300: C951-C967.
[9] Huang H, Pugsley MK, Fermini B, et al. Cardiac voltage-gated ion channels in safety pharmacology: review of the landscape leading to the CiPA initiative[J]. J Pharmacol Toxicol Methods, 2017, 87: 11-23.
[10] Lee W, Windley MJ,Vandenberg JI, et al. In vitro and in silico risk assessment in acquired long QT syndrome: the devil is in the details[J]. Front Physiol, 2017, 8: 934.
[11] Warmke JW, Ganetzky B. A family of potassium channel genes related to EAG in drosophila and mammals[J]. Proc Natl Acad Sci USA, 1994, 91: 3438-3442.
[12] Sanguinetti MC, Jiang C, Curran ME, et al. A mechanistic link between an inherited and an acquired cardiac arrhythmia: hERG encodes the Ikr potassium channel[J]. Cell, 1995, 81: 299-307.
[13] Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia[J]. Nature, 2006, 440: 463-469.
[14] Smith JL, McBride CM, Nataraj PS, et al. Trafficking-deficient hERG K+ channels linked to long QT syndrome are regulated by a microtubule-dependent quality control compartment in the ER[J]. Am J Physiol Cell Physiol, 2011, 301: 75-85.
[15] Foo B, Williamson B, Young JC, et al. hERG quality control and the long QT syndrome[J]. J Physiol, 2016, 594: 2469-2481.
[16] Wang W, MacKinnon R. Cryo-EM structure of the open human ether-à-go-go-related K+ channel hERG[J]. Cell, 2017, 169: 422-430.
[17] Vandenberg JI, Perry MD, Perrin MJ, et al. hERG K+ channels: structure, function and clinical significance[J]. Physiol Rev, 2012, 92: 1393-1478.
[18] Kalyaanamoorthy S, Barakat KH. Development of safe drugs: the hERG challenge[J]. Med Res Rev, 2018, 38: 525-555.
[19] Zhang Y, Dong Z, Jin L, et al. Arsenic trioxide-induced hERG K+ channel deficiency can be rescued by matrine and oxymatrine through up-regulating transcription factor Sp1 expression[J]. Biochem Pharmacol, 2013, 85: 59-68.
[20] Dennis A, Wang L, Wan X, et al. hERG channel trafficking: novel targets in drug-induced long QT syndrome[J]. Biochem Soc Trans, 2007, 35: 1060-1063.
[21] de Git KC, de Boer TP, Vos MA, et al. Cardiac ion channel trafficking defects and drugs[J]. Pharmacol Ther, 2013, 139: 24-31.
[22] Yan M, Feng L, Shi Y, et al. Mechanism of As2O3-induced action potential prolongation and using hiPS-CMs to evaluate therescue efficacy of drugs with different rescue mechanism[J]. Toxicol Sci, 2017, 158: 379-390.
[23] Cai C,Guo P,Zhou Y,et al.Deep learning-based prediction of drug-induced cardiotoxicity[J]. J Chem Inf Model, 2019, 59: 1073-1084.
[24] Liu L, Li XH, Wang W, et al. Advances in research on arrhythmogenic Chinese medicine[J]. Med Inform (医学信息), 2014, 27: 648-649.
[25] Orvos P, Virág L, Tálosi L, et al. Effects of Chelidonium majus extracts and major alkaloids on hERG potassium channels and on dog cardiac action potential-a safety approach[J]. Fitoterapia, 2015, 100: 156-165.
[26] Harmati G, Papp F, Szentandrássy N, et al. Effects of the PKC inhibitors chelerythrine and bisindolylmaleimide I (GF109203X) on delayed rectifier K+ currents[J]. Naunyn Schmiedebergs Arch Pharmacol, 2011, 383: 141-148.
[27] Li Y, Wang L, Cheng R, et al. Anti-arrhythmia effect of crypto-alkali and its effect on action potential[J]. Chin J Mult Organ Dis Elder (中华老年多器官疾病杂志), 2005, 4: 123-126.
[28] Zhao XL, Gu DF, Qi ZP, et al. Comparative effects of sophocarpine and sophoridine on hERG K+ channel[J]. Eur J Pharmacol, 2009, 607: 15-22.
[29] Chen Y, Huang X, Wei CL, et al. Effect of puerarin on action potential and delayed rectifier potassium current of guinea pig papillary muscle[J]. Chin Pharm J (中国药学杂志), 2006, 41: 747-749.
[30] Sun X, Xu B, Xue Y, et al. Characterization and structure-activity relationship of natural flavonoids as hERG K+ channel modulators[J]. Int Immunopharmacol, 2017, 45: 187-193.
[31] Cyranoski D. Arsenic patent keeps drug for rare cancer out of reach of many[J]. Nat Med, 2007, 13: 1005.
[32] Shinnawi R, Gepstein L. iPCS cell modeling of inherited cardiac arrhythmias[J]. Curr Treat Opt Cardiovascular Med, 2014, 16: 331.
[33] Dong Z, Shi Y, Feng L, et al. (-)-Epicatechin rescues the As2O3-induced hERG K+ channel deficiency possibly through upregulating transcription factor SP1 expression[J]. J Biochem Mol Toxicol, 2017, 31: e21966.
[34] Zhao X, Feng T, Shen H, et al. Arsenic trioxide-induced apoptosis in h9c2 cardiomyocytes: implications in cardiotoxicity[J]. Basic Clin Pharmacol Toxicol, 2008, 102: 419-425.
[35] Zhao XY, Li GY, Yang BF, et al. Resveratrol protects against arsenic trioxide-induced cardiotoxicity in vitro and in vivo[J]. Br J Pharmacol, 2008, 154: 105-113.
[36] Chu W, Li C, Qu X, et al. Arsenic-induced interstitial myocardial fibrosis reveals a new insight into drug-induced long QT syndrome[J]. Cardiovascular Res, 2012, 96: 90-98.
[37] Jiang Y, Du W, Chu Q, et al. Downregulation of long non-coding RNA Kcnq1ot1: an important mechanism of arsenic trioxide-induced long QT syndrome[J]. Cell Physiol Biochem, 2018, 45: 192-202.
[38] Yu D, Lv L, Fang L, et al. Inhibitory effects and mechanism of dihydroberberine on hERG channels expressed in HEK293 cells[J]. PLoS One, 2017, 12: e0181823.
[39] Zhang K, Zhi D, Huang T, et al. Berberine induces hERG channel deficiency through trafficking inhibition[J]. Cell Physiol Biochem, 2014, 34: 691-702.
[40] Li BX, Yang BF, Zhou J, et al. Inhibition of berberine on IK1, IK and hERG channels in cardiomyocytes[J]. Chin Pharm J (中国药学杂志), 2001, 36: 33-39.
[41] Zhang Y, Colenso CK, El Harchi A, et al. Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking[J]. Biochem Pharmacol, 2016, 113: 24-35.
[42] Zhi D, Feng PF, Sun JL, et al. The enhancement of cardiac toxicity by concomitant administration of Berberine and macrolides[J]. Eur J Pharm Sci, 2015, 76: 149-155.
[43] Lin JJ, Wang J, Shen T, et al. Advances in pharmacological effects of Wujing alkaloids on cardiovascular[J]. Chin J Clin Res(中国临床研究), 2015, 28: 1392-1393.
[44] Baburin I, Varkevisser R, Schramm A, et al. Dehydroevodiamine and hortiamine, alkaloids from the traditional Chinese herbal drug Evodia rutaecarpa, are I Kr blockers with proarrhythmic effects in vitro and in vivo [J]. Pharmacol Res, 2018, 131: 150-163.
1.刘昕彦, 邵瑞, 贺爽, 朱彦.类器官和立体细胞模型在中药心脏毒性评价中的应用前景[J]. 药学学报, 2019,54(11): 1888-1894